Probiotics in the Rescue of Gut Inflammation

Therapeutic, Probiotic, and Unconventional Foods

Volumn , Issue , 2018, Pages 101-116

  Ghosh, Asit Ranjan ^a  

^a VIT UNIVERSITY   (India)

Author keywords

Biohydrogenation; Dysbiosis; Gut; Inflammation; Microbiota; Probiotics

Indexed keywords

EID: 85061332684     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-814625-5.00006-6     Document Type: Chapter

References (156)

1. Abdin A.A., Saeid E.M. An experimental study on ulcerative colitis as a potential target for probiotic therapy by Lactobacillus acidophilus with or without "olsalazine". J. Crohns. Colitis. 2008, 2:296-303.
2. Adams A.C. The probiotic paradox: live and dead cells are biological response modifiers. Nutr. Res. Rev. 2010, 23:37-46.
3. Alipour B., Homayouni-Rad A., Vaghef-Mehrabany E., et al. Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial. Int. J. Rheum. Dis. 2014, 17:519-527.
4. Amar J., Chabo C., Wagget D., Aurelie K., Vachoux C., Bermúdez-Humarán L.G., et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanism and probiotic treatment. EMBO Mol. Med. 2011, 3:559-572.
5. Anderson R., Cookson A., McNabb W., Park Z., McCann M., Kelly W., Roy N. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol. 2010, 10:316.
6. Ang Z., Ding J.L. GPR41 and GPR43 in obesity and inflammation-protective or causative?. Front. Immunol. 2016, 7. 10.3389/fimmu.2016.00028.
7. Armougom F., Henry M., Vialettes B., Raccah D., Raoult D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and methanogens in anorexic patients. PLoS One 2009, 4.
8. Arumugam M., Raes J., Pelletier E., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
9. Arunachalam K., Gill H.S., Chandra R.K. Enhancement of natural immune function by dietary consumption of Bifdobacterium lactis (HN019). Eur. J. Clin. Nutr. 2000, 54:263-267.
10. van Baarlen P., Wells J.M., Kleerebezem M. Regulation of intestinal homeostasis and immunity with probiotic lactobacilli. Trends Immunol. 2013, 34:208-215. 10.1016/j.it.2013.01.005.
11. Backhed F., Manchester J.K., Semenkovich C.F., Gordon J.I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:979-984.
12. Bagad M., Pande R., Ghosh A.R. Determination of viability of Pedicoccus spp. GS4 after storage into hard gelatin capsule and its survival under in vitro stimulated gastrointestinal condition. Intl. J. Res. Ayur. Pharma. 2012, 3:233-237.
13. Bakken J.S., Borody T., Brandt L.J., Brill J.V., Demarco D.C., Franzos M.A., Kelly C., Khoruts A., Louie T., Martinelli L.P., Moore T.A., Russell G., Surawicz C. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. 2011, 9:1044-1049.
14. Bassaganya-Riera J., Viladomiu M., Pedragosa M., de Simone C., Carbo A., et al. Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPARγ to suppress colitis. PLoS One 2012, 7. 10.1371/journal.pone.0031238.
15. Bengmark S. Econutrition and health maintenance-a new concept to prevent GI inflammation, ulceration and sepsis. Clin. Nutr. 1996, 15:1-10.
16. Bermon S., Petriz B., Kajeniene A., Prestes J., Castell L., Franco O.L. The microbiota: an exercise immunology perspective. Exerc. Immunol. Rev. 2015, 21:70-79.
17. Bested A.C., Logan A.C., Selhub E.M. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances. Part III-convergence toward clinical trials. Gut Pathog. 2013, 5:4.
18. Boccardo F., Lunardi G., Guglielmini P., et al. Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. Eur. J. Cancer 2004, 40:84-89.
19. Brenner D.M., Chey W.D. Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. Rev. Gastroenterol. Disord. 2009, 9:7-15.
20. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
21. Cani P.D., Bibiloni R., Knauf C., Waget A., Neyrinck A.M., Delzenne N.M., Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
22. Cani P.D., Delzenne N.M. The gut microbiome as therapeutic target. Pharmacol. Therap. 2011, 130:202-212.
23. Carding S., Verbeke K., Vipond D.T., Corfe B.M., Owen L.J. Dysbiosis of the gut microbiota in disease. Microbial Ecol. Hlth. Dis. 2015, 26(26191). https://doi.org/10.3402/mehd.v26.26191.
24. Carol M., Borruel N., Antolin M., Llopis M., Casellas F., Guarner F., et al. Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease. J. Leukoc. Biol. 2006, 79:917-922.
25. Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.-H., Packey C.D., Sartor R.B., Ringel Y. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301:G799-G807.
26. Chang J.Y., Antonopoulos D.A., Kalra A., Tonelli A., Khalife W.T., Schmidt T.M., Young V.B. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 2008, 197:435-438.
27. Chey W.D., Kurlander J., Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015, 313:949-958. 10.1001/jama.2015.0954.
28. Chirivi R.G.S., van Rosmalen J.W.G., Jenniskens G.J., Pruijin G.J., Raats J.M.H. Citrullination: a target for disease intervention in multiple sclerosis and other inflammatory diseases?. J. Clin. Cell. Immunol. 2013, 4:146.
29. Clayton T.A., Baker D., Lindon J.C., Everett J.R., Nicholson J.K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14728-14733.
30. Dai C., Zheng C.Q., Meng F.J., Zhou Z., Sang L.X., Jiang M. VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis. Mol. Cell. Biochem. 2013, 374:1-11. 10.1007/s11010-012-1488-3.
31. Daliri E.B.-M., Lee B.H. New perspectives on probiotics in health and disease. Food Sci. Human Wellness 2015, 4:56-65.
32. David L.A., Maurice C.F., Carmody R.N., Gootenberg D.B., Button J.E., Wolfe B.E., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505:559-563. 24336217. https://doi.org/10.1038/nature12820.
33. d'Ettorre G., Ceccarelli G., Giustini N., Serafino S., Calantone N., De Girolamo G., et al. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: results of the "Probio-HIV" clinical trial. PLoS One 2015, 10. 10.1371/journal.pone.0137200.
34. Delcenserie V., Martel D., Lamoureux M., Amiot J., Boutin Y., Roy D. Immunomodulatory effects of probiotics in the intestinal tract. Curr. Issues Mol. Biol. 2008, 10:37-54.
35. de los Angeles P.M., Thijs C., van den Brandt P.A., et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA birth cohort study. Gut 2007, 56:661-667.
36. de los Angeles P.M., Thompson S.F., Summers K., de Leon F., Pope J., Reid G.A. Randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Med. Sci. Monit. 2011, 17:347-354.
37. Dethlefsen L., Huse S., Sogin M.L., Relman D.A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008, 6.
38. Dev S., Mizuguchi H., Das A.K., Matsushita C., Maeyama K., Umehara H., et al. Suppression of histamine signalling by probiotic Lac-B: a possible mechanism of its anti-allergic effect. J. Pharmacol. Sci. 2008, 107:159-166.
39. Dicksved J., Halfvarson J., Rosenquist M., Järnerot G., Tysk C., Apajalahti J., et al. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J. 2008, 2:716-727.
40. Distrutti E., Cipriani S., Mencarelli A., Renga B., Fiorucci S. Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. PLoS One 2013, 8.
41. Duary R.K., Bhausaheb M.A., Batish V.K., Grover S. Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic Lactobacillus plantarum Lp91 in colitis mouse model. Mol. Biol. Rep. 2012, 39:4765-4775.
42. Dubey V., Ghosh A.R. Probiotic potential and surface active component like s-layer proteins (slps) in LAB isolates [DFM04] 2011.
43. Dubey V., Ghosh A.R. Nexus between chronic inflammation and cancer. J. Pharm. Res. 2012, 5:1374-1379.
44. Dubey V., Ghosh A.R. Probiotics cross talk with multi cell signaling in colon carcinogenesis. J. Prob. Hlth. 2013, 1:109-113. 10.4172/2329-8901.1000109.
45. Dubey V., Ghosh A.R., Bishayee K., Khuda-Bukhsh A.R. Probiotic Pediococcus pentosaceus strain GS4 alleviates azoxymethane induced toxicity in mice. Nutr. Res. 2015, 35:921-929. 10.1016/j.nutres.2015.08.001.
46. Dubey V., Ghosh A.R., Bishayee K., Khuda-Bukhsh A.R. Appraisal of the anti-cancer potential of probiotic Pediococcuspentosaceus GS4 against colon cancer: in vitro and in vivo approaches. J. Funct. Foods 2016, 23:66-79.
47. Dubey V., Ghosh A.R., Mandal B.K. Appraisal of conjugated linoleic acid production by probiotic potential of Pediococcus spp. GS4. Appl. Biochem. Biotechnol. 2012, 168:1265-1276.
48. Dvorožňáková E, Bucková B, Hurníková Z, Revajová V, Lauková A. Effect of probiotic bacteria on phagocytosis and respiratory burst activity of blood polymorphonuclear leukocytes (PMNL) in mice infected with Trichinella spiralis. Vet. Parasitol. 2016 Jul 7. pii: S0304-4017(16)30263-1. https://doi.org/10.1016/j.vetpar.2016.07.004.
49. Eckburg P.B., Bik E.M., Bernstein C.N., Purdom E., Dethlefsen L., Sargent M., Gill S.R., Nelson K.E., Relman D.A. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
50. Enck P., Zimmermann K., Menke G., Klosterhalfen S. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E. Coli preparation (DSM17252) compared to placebo. Z. Gastroenterol. 2009, 47:209-214.
51. Falcinelli S., Picchietti S., Rodiles A., Cossignani L., Merrifield D.L., Taddei A.R. Lactobacillus rhamnosus lowers zebrafish lipid content by changing gut microbiota and host transcription of genes involved in lipid metabolism. Sci. Rep. 2015, 5. 10.1038/srep09336.
52. Fernandez E.M., Valenti V., Rockel C., Hermann C., Pot B., Boneca I.G., Grangette C. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut 2011, 60:1050-1059.
53. Festi D., Schiumerini R., Eusebi L.H., Marasco G., Tassia M., Colecchia A. Gut microbiota and metabolic syndrome. World J. Gastroenterol. 2014, 20:16079-16094.
54. de Filippo C., Cavalieri D., Di Paola M., Ramazzotti M., Poullet J.B., Massart S., et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14691-14696.
55. Frank D.N., St.Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R. Molecular phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13780-13785.
56. Fujimori S., Tatsuguchi A., Gudis K., Kishida T., Mitsui K., Ehara A., Kobayashi T., Sekita Y., Seo T., Sakamoto C. High dose probiotic and prebiotic co-therapy for remission induction of active Crohn's disease. J. Gastroenterol. Hepatol. 2007, 22:1199-1204.
57. Garrett W.S., Lord G.M., Punit S., et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007, 131:33-45. 10.1016/j.cell.2007.08.017.
58. Ghosh A.R., Dubey V. Immunologic approach to elucidate surface antigens and secondary metabolites in probiotics 2014.
59. Gophna U., Sommerfeld K., Gophna S., Doolittle W.F., Veldhuyzen van Zanten S.J. Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J. Clin. Microbiol. 2006, 44(11):4136-4141.
60. Gowri S., Ghosh A.R. Pediococcus spp.-a potential probiotic isolated from Khadi (an Indian fermented food) and identified by 16S rDNA sequence analysis. Afr. J. Food Sci. 2010, 4:597-602.
61. Gowri S., Ghosh A.R. Study of the probiotic potential of lactic acid bacteria isolated from a variety of Indian fermented food. J. Pharm. Res. 2010, 3:2254-2257.
62. Gowri S., Ghosh A.R. Ready to eat curd-a step towards rural transformation. J. Prob. Health 2013, 1(3):1-5. https://doi.org/10.4172/2329-8901.1000111.
63. Greer J.B., O'Keefe S.J. Microbial induction of immunity, inflammation, and cancer. Front. Physiol. 2011, 1:1-8. 10.3389/fphys.2010.00168.
64. Groeger D., O'Mahony L., Murphy E.F., Bourke J.F., Dinan T.G., Kiely B., Shanahan F., Quigley E.M. Bifidobacterium infantis 35624 modulates inflammatory processes beyond the gut. Gut Microbes 2013, 4:325-339.
65. Hakansson A., Molin G. Gut microbiota and inflammation. Nutrients 2011, 3:637-682. 10.3390/nu3060637.
66. Haller D., Bode C., Hammes W.P., Pfeiter A.M., Schiffin E.J., Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/ ceucocyte co-cultures. Gut 2000, 47:79-87.
67. Hänsch, G. M. 2012. Host defence against bacterial biofilms: "Mission impossible"? ISRN Immunol. Art.Id 853123, 1-17. http://doi.org/10.5402/2012/85312.
68. Hansen J., Gulati A., Sartor R.B. The role of mucosal immunity and host genetics in defining intestinal commensal bacteria. Curr. Opin. Gastroenterol. 2010, 26:564-571.
69. Hawrelak J.A., Myers S.P. The causes of intestinal dysbiosis: a review. Altern. Med. Rev. 2004, 9:181-197.
70. Hegazy S.K., El-Bedewy M.M. Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J. Gastroenterol. 2010, 16:4145-4151.
71. Hermann C., Spreitzer I., Schröder N.W., Morath S., Lehner M.D., Fischer W., et al. Cytokine induction by purified lipoteichoic acids from various bacterial species-role of LBP, sCD14, CD14 and failure to induce IL-12 and subsequent IFN-gamma release. Eur. J. Immunol. 2002, 32:541-551.
72. Honad K., Litman D.R. The microbime in infectious diseases and inflammation. Annu. Rev. Immunol. 2012, 30:758-795.
73. Hormannsperger G., Haller D. Molecular crosstalk of probiotic bacteria with the intestinal immune system: clinical relevance in the context of inflammatory bowel disease. Intl. J. Med. Microbiol. 2010, 300:63-73.
74. Huey-Shi L., Chiu-Yin K., Joo-Ann E., Wai-Yee F., Min-Tze L. The improvement of hypertension by probiotics: effects on cholesterol, diabetes, renin, and phytoestrogens. Int. J. MolSci. 2009, 10:3755-3775. 10.3390/ijms10093755.
75. Imaoka A., Shima T., Kato K., Mizuno S., Uehara T., Matsumoto S., Setoyama H., Hara T., Umesaki Y. Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. World J. Gastroenterol. 2008, 14:2511-2516.
76. Jakobsson H.E., Rodríguez-Piñeiro A.M., Schütte A., et al. The composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep. 2015, 16:164-177.
77. Jakoby W.B., Ziegler D.M. The enzymes of detoxication. J. Biol. Chem. 1990, 265:20715-20718. PMID. 2249981.
78. Kalliomäki M., Collado M.C., Salminen S., Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am. J. Clin. Nutr. 2008, 87:534-538. (18326589).
79. Kamada N., Seo S.U., Chen G.Y., Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 2013, 13:321-335.
80. Kang H.-J., Im S.-H. Probiotics as an immune modulator. J. Nutr. Sci. Vitaminol. 2015, 61:S103-S105.
81. Khailova L., Frank D.N., Dominiguez J.A., Wischmeyer P.E. Probiotic administration reduces mortality and improves intestinal epithelial homeostasis in experimental sepsis. Anesthesiology 2013, 119:166-177.
82. Klein G.L., Petschow B.W., Shaw A.L., Weaver E. Gut barrier dysfunction and microbial translocation in cancer cachexia: a new therapeutic target. Curr. Opin. Support Palliant. Care 2013, 7:361-367.
83. Knights D., Parfrey L.W., Zaneveld J., Lozupone C., Knight R. Human-associated microbial signatures: examining their predictive value. Cell Host Microbe 2011, 10:292-296.
84. Koboziev I., Webb C.R., Furr K.L., Grisham M.B. Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Rad. Biol. Med. 2014, 68:122-133.
85. Kwon H.-K., Lee C.-G., So J.-S., Chae C.-S., Hwang J.-S., Sahoo A., Nam J.H., Rhee J.H., Hwang K.-C., Im S.-H. Generation of regulatory dendritic cells and CD4+ FoxP3+T cells by probiotics administration suppresses immune disorders. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2159-2164.
86. Lammers K.M., Helwig U., Swennen E., Rizzello F., Venturi A., Caramelli E., et al. Effects of probiotic strains on interleukin 8 produced by HT29/19A cells. Am. J. Gastroenterol. 2002, 97:1182-1186.
87. Larsen N., Vogensen F.K., van den Berg F.W., Nielsen D.S., Andreasen A.S., Pedersen B.K., Al-Soud W.A., Sørensen S.J., Hansen L.H., Jakobsen M. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010, 5. pmid:20140211, 10.1371/journal.pone.0009085.
88. Lebeer S., Vanderleyden J., De Keersmaecker S. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat. Rev. Microbiol. 2010, 8:171-184.
89. Lescheid D.W. Probiotics as regulators of inflammation: a review. Func. Food Hlth. Dis. 2014, 4:299-311.
90. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023. 10.1038/4441022a.
91. Lozupone C.A., Stombaugh J.I., Gordon J.I., Janson J.K., Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012, 489:220-230. 10.1038/nature11550.
92. Lyte M. Microbial endrocrinology: host-microbiota interactions influencing brain and behaviour. Gut Microbes 2014, 5:381-389.
93. Madsen K.L. Enhancement of epithelial barrier function by probiotics. J. Epithelial Biol. Pharmacol. 2012, 5:55-59.
94. Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011, 474:298-306.
95. Marteau P. Probiotics, prebiotics, synbiotics: ecological treatment for inflammatory bowel disease?. Gut 2006, 55:1692-1693.
96. Maslowski K.M., Vieira A.T., Ng A., Kranich J., Sierro F., Yu D., Schilter H.C., Rolph M.S., Mackay F., Artis D., Xavier R.J., Teixeira M.M., Mackay C.R. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461:1282-1286.
97. Matsuguchi T., Takagi A., Matsuzaki T., et al. Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor α-inducing activities in macrophages through Toll-like receptor 2. Clin. Diagn. Lab. Immunol. 2003, 10:259-266.
98. Mayer, E. A., Knight, R., Mazmanian, S. K., Cryan, J. F., Tillisch, K. 2014. Gut microbes and the brain: paradigm shift in neuroscience. J. Neurosci. 34, 15490-15496. doi: 10.1523/JNEUROSCI.3299-14.2014. PMCID: PMC4228144.
99. Maynard C.L., Elson C.O., Hatton R.D., Weaver C.T. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012, 489:231-241. 10.1038/nature11551.
100. Meng J., Zhu X., Gao S.M., Zhang Q.X., Sun Z., Lu R.R. Characterization of surface layer proteins and its role in probiotic properties of three Lactobacillus strains. Int. J. Biol. Macromol. 2014, 65:110-114. 10.1016/j.ijbiomac.2014.01.024.
101. Mikami K., Takahashi H., Kimura M., et al. Influence of maternal bifidobacteria on the establishment of bifidobacteria colonizing the gut in infants. Pediatr. Res. 2009, 65:669-674.
102. Mishra A.K., Dubey V., Ghosh A.R. Obesity: an overview of possible role(s) of gut hormones, lipid sensing and gut microbiota. Metabolism 2016, 65:48-65. https://doi.org/10.1016/j.metabol.2015.10.008.
103. Miyauchi E., Morita H., Tanabe S. Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo. J. Dairy Sci. 2009, 92:2400-2408.
104. Mohamadzadeh M., Olson S., Kalina W.V., Ruthel G., Demmin G.L., Warfield K.L., et al. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2880-2885.
105. Mukhopadhyay I., Hansen R., El-Omar E.M., Hold G.L. IBD-what role do Proteobacteria play?. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:219-230.
106. Nadal I., Donant E., Ribes-Koninckx C., Calabuig M., Sanz Y. Imbalance in the composition of the duodenal microbiota of children with coeliac disease. J. Med. Microbiol. 2007, 56:1669-1674.
107. Nicolau J., Masmiquel L. Diabetes mellitus and depressive disorder, an undesirable association. Endocrinol. Nutr. 2013, 60:583-589.
108. Ogawa T., Asai Y., Tamai R., Makimura Y., Sakamoto H., Hasikawa S., Yasuda K. Natural killer cell activities of symbiotic Lactobacillus casei spp. casei in conjuction with dextran. Clin. Exp. Immunol. 2006, 143:103-109.
109. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72:219-246.
110. Pande R., Bagad M., Dubey V., Ghosh A.R. Prospectus of probiotics in modern age diseases. Asian Pacific J Trop. Biomed. 2012, S1963-S1974.
111. Park J.H., Um J.I., Lee B.J., Goh J.S., Park S.Y. Encapsulated Bifidobacterium bifidum potentiates intestinal IgA production. Cell. Immunol. 2002, 219:22-27.
112. Peterson C.T., Sharma V., Elmén L., Peterson S.N. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin. Exp. Immunol. 2014, 79:363-377.
113. Pirhaji L., Milani P., Leidl M., Curran T., Avila-Pacheco J., Clish C.B., et al. Revealing disease-associated pathways by network integration of untargeted metabolomics. Nature Meth. 2016, 10.1038/nmeth.3940.
114. Plaza-Diaz J., Gomez-Llorente C., Fontana L., Gil A. Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics. World J. Gastroenterol. 2014, 20:15632-15649.
115. Rao R.K., Samak G. Protection and restitution of gut barrier by probiotics: nutritional and clinical implications. Curr. Nutr. Food Sci. 2013, 9:99-107.
116. Ratner M. Fecal transplantation poses dilemma for FDA. Nature Biotech. 2014, 32:401-402. 10.1038/nbt0514-401.
117. Rigby R.J., Knight S.C., Kamm M.A., Stagg A.J. Production of interleukin (IL)-10 and IL-12 by murine colonic dendritic cells in response to microbial stimuli. Clin. Exp. Immunol. 2005, 139:245-256.
118. Roesch L.F.W., Lorca G.L., Casella G., et al. Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J. 2009, 3:536-548.
119. Round J.L., Mazmanian S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nature Rev. Immun. 2009, 9:313-323.
120. Ruiz P.A., Hoffmann M., Szcesny S., Blaut M., Haller D. Innate mechanisms for Bifidobacterium lactis to activate transient pro-inflammatory host responses in intestinal epithelial cells after the colonization of germ-free rats. Immunology 2005, 115:441-450.
121. Saarela M., Mogensen G., Fonden R., Matto J., Mattila-Sandholm T. Probiotic bacteria: safety, functional and technological properties. J. Biotechnol. 2000, 84:197-215.
122. Sakai Y., Tsukahara T., Bukawa W., et al. Cell preparation of Enterococcus faecalis strain EC-12 prevents vancomycin-resistant enterococci colonization in the cecum of newly hatched chicks. Poult. Sci. 2006, 85:273-277.
123. Salinas I., Meseguer J., Esteban A. Antiproliferative effects and apoptosis induction by probiotic cytoplasmic extracts in fish cell lines. Vet. Microbiol. 2008, 126:287-294.
124. Salminen, S., Bouley, C., Boutron-Ruault, M.C, et al. 1998. Functional food science and gastrointestinal physiology and function. Brit J. Nutr. 80, S147-S171. doi:10.1079/BJN19980108.
125. Scanlan P.D., Shanahan F., Clune Y., et al. Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ. Microbiol. 2008, 10:789-798.
126. Scharlau D., Borowicki A., Habermann N., Hofmann T., Klenow S., Miene C., Munjal U., Stein K., Glei M. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. Mutat. Res. 2009, 682:39-53. 10.1016/j.mrrev.2009.04.001.
127. Schlee M., Harder J., Koten B., Stange E.F., Wehkamp J., Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin. Exp. Immunol. 2008, 151:528-534.
128. Schwiertz A., Taras D., Schäfer K., Beijer S., Bos N.A., Donus C., Hardt P.D. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 2010, 18:190-195. pmid:19498350, 10.1038/oby.2009.167.
129. Selhub E.M., Logan A.C., Bested A.C. Fermented foods, microbiota, and mental health: ancient practice meets nutritional psychiatry. J. Physiol. Anthropol. 2014, 33:2-12.
130. Shadnoush M., Shaker Hosseini R., Mehrabi Y., Delpisheh A., Alipoor E., Faghfoori Z., Mohammadpour N., Zaringhalam Moghadam J. Probiotic yogurt affects pro- and antinflammatory factors in patients with inflammatory bowel disease. Iran. J. Pharm. Res. 2013, 12:929-936.
131. Sheil B., McCarthy J., O'Mahony L., Bennett M.W., Ryan P., Fitzgibbon J.J., Kiely B., Collins J.K., Shanahan F. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 2004, 53:694-700.
132. Shruthy V.V., Pavithra M., Gowri S., Ghosh A.R. Probiotic potentials among lactic acid bacteria isolated from curd. Intl. J. Res. Ayur. Pharm. 2011, 2:602-609.
133. Sindhu K.N., Sowmyanarayanan T.V., Paul A., Baji S., Ajjampur S.S., Priyadarshini S., et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG (LGG): a randomized, double blinded, placebo-controlled trial. Clin. Infect. Dis. 2014, 58:1107-1115.
134. Snydman D.R. The safety of probiotics. Clin. Infect. Dis. 2008, 46:S104-S111.
135. Strober W., Fuss I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterol. 2011, 140:1756-1767.
136. Sturm A., Rilling K., Baumgart D.C., Gargas K., Abou-Ghazale T., et al. Escherichia coli Nissle 1917 distinctively modulates T cell cycling and expansion via toll-like receptor 2 signaling. Infect. Immun. 2005, 73:1452-1465.
137. Sun Y., Cai Y., Mai V., Farmerie W., Yu F., Li J., Goodison S. Advanced computational algorithms for microbial community analysis using 16S rRNA sequence data. Nucl. Acids Res. 2010, 38.
138. Swidsinski A., Weber J., Loening-Baucke V., Hale L.P., Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J. Clin. Microbiol. 2005, 43:3380-3389.
139. Thirabunyanon M., Boonprasom P., Niamsup P. Probiotic potential of lactic acid bacteria isolated from fermented dairy milks on antiproliferation of colon cancer cells. Biotechnol. Lett. 2009, 31:571-576.
140. Thomas C.M., Versalovic J. Probiotics-host communication: modulation of signaling pathways in the intestine. Gut Microbes 2010, 1:148-163.
141. Tien M.T., Girardin S.E., Regnault B., Le Bourhis L., Dilles M.A., Coppee J.Y., Bourdet-Sicard R., Sansonneti P.J., Pedron T. Anti-inflammatory effects of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J. Immunol. 2006, 176:1228-1237.
142. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
143. Ukena S.N., Singh A., Dringenberg U., Engelhardt R., Seidler U., Hansen W., Bleich A., Bruder D., Franzke A., Rogler G., Suerbaum S., Buer J., Gunzer F., Westendorf A.M. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007, 2.
144. Vaahtovuo J., Munukka E., Korkeamäki M., Luukkainen R., Toivanen P. Fecal microbiota in early rheumatoid arthritis. J. Rheumatol. 2008, 35:1500-1505.
145. Vinderola G., Matar C., Perdigon G. Role of intestinal epithelial cells in immune effects mediated by gram-positive probiotic bacteria: involvement of toll-like receptors. Clin. Diagn. Lab. Immunol. 2005, 12:1075-1084.
146. de Waard R., Classen E., Bokken G.C., Buiting B., Garssen J., Vos J.G. Enhanced immunological memory responses to Listeria monocytogenes in rodents, as measured by delayed-type hypersensitivity (DTH), adoptive transfer of DTH, and protective immunity following Lactobacillus casei Shirota ingestion. Clin. Diagn. Lab. Immunol. 2003, 10:59-65.
147. Wagner C.L., Taylor S.N., Johnson D. Host factors in amniotic fluid and breast milk that contribute to gut maturation. Clin. Rev. Allergy Immunol. 2008, 34:191-204.
148. Wang M., Molin G., Ahrné S., Adawi D., Jeppsson B. High proportions of proinflammatory bacteria on the colonic mucosa in a young patient with ulcerative colitis as revealed by cloning and sequencing of 16S rRNA genes. Dig. Dis. Sci. 2007, 52:620-627.
149. Wen L., Ley R.E., Volchkov P.V., Stranges P.B., Avanesyan L., Stbraker A.C., et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008, 455:1109-1113.
150. Wikipedia. n.d. https://en.wikipedia.org/wiki/Irritable_bowel_syndrome#Epidemiology.
151. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431-1433.
152. Wu G.D., Chen J., Hoffmann C., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011, 334:105-108. 10.1126/science.1208344.
153. Xiong Y., Miyamoto N., Shibata K., Valasek M.A., Motoike T., Kedzierski R.M., Yanagisawa M. Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:1045-1050.
154. Young V.B., Schmidt T.M. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J. Clin. Microbiol. 2004, 42:1203-1206.
155. Zhang L., Li N., Caicedo R., Neu J. Alive and dead Lactobacillus rhamnosus GG decreases tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. J. Nutr. 2005, 135:1752-1756.
156. Zyrek A.A., Cichon C., Helms S., Enders C., Sonnenborn U., Schmidt M.A. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKC zeta redistribution resulting in tight junction and epithelial barrier repair. Cell. Microbiol. 2007, 9:804-816.